藥明康德(603259.SH):在過去沒有、現在和未來都不會對美國構成國家安全風險
格隆匯2月18日丨藥明康德(603259.SH)公佈澄清公吿,公司注意到,有美國議員於2024年2月12日致函美國商務部、財政部和國防部,其內容有關本公司。本公司一向歡迎監管機構對我們所在行業的監管,我們公司過去亦多次成功通過美國政府的審查。但是,本公司強烈反對針對我們公司的誤導性指稱、不確實認定和未經正當程序的預判行動。
本公司堅信,藥明康德在過去沒有、現在和未來都不會對美國構成國家安全風險,即使美國政府再次對本公司進行審查亦將得出相同結論。事實上,藥明康德是全球製藥和生命科學行業的重要貢獻者之一。
公司關於澄清事項的進一步表示,“WuXi AppTec Co.,
Ltd.”為本公司英文名稱。“Wuxi”或者“WuXi”並非本公司名稱,而是城市“無錫”的漢語拼音。無錫市位於中國東部的長江三角洲,距離上海約130公里。作為一家註冊於無錫市的外商投資股份有限公司,我們在二十多年前從該地開始了本公司的醫藥研發合同外包服務(CRO)業務。
本公司亦籍此重申,本公司沒有人類基因組學業務,現有各類業務不會收集人類基因組數據。我們提供基於合同的研究、開發和生產服務,通過賦能全球製藥和生命科學行業,致力於推動新藥研發併為患者帶來挽救生命的新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.